메뉴 건너뛰기




Volumn 105, Issue 15, 2013, Pages 1078-1085

Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

EID: 84881657754     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt182     Document Type: Article
Times cited : (31)

References (50)
  • 1
    • 79958043675 scopus 로고    scopus 로고
    • National Cancer Institute Accessed August 26, 2011
    • National Cancer Institute. SEER Cancer Statistics Review 1975-2008. http://seer.cancer.gov/statistics/. Accessed August 26, 2011.
    • SEER Cancer Statistics Review 1975-2008
  • 2
    • 85081792750 scopus 로고    scopus 로고
    • National Cancer Institute Accessed August 26, 2011
    • National Cancer Institute. A Snapshot of Lymphoma. http://www.cancer. gov/aboutnci/servingpeople/snapshots/lymphoma.pdf. Accessed August 26, 2011.
    • A Snapshot of Lymphoma
  • 5
    • 0037394103 scopus 로고    scopus 로고
    • Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-hodgkin's lymphoma
    • Pettengell R, Linch D, Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-hodgkin's lymphoma. Br J Haematol. 2003;121(1):44-48.
    • (2003) Br J Haematol , vol.121 , Issue.1 , pp. 44-48
    • Pettengell, R.1    Linch, D.2
  • 6
    • 24644500086 scopus 로고    scopus 로고
    • Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
    • Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033.
    • (2005) J Clin Oncol , vol.23 , Issue.22 , pp. 5027-5033
    • Sehn, L.H.1    Donaldson, J.2    Chhanabhai, M.3
  • 7
    • 79951816939 scopus 로고    scopus 로고
    • Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America
    • Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.
    • (2011) Clin Infect Dis , vol.52 , Issue.4
    • Freifeld, A.G.1    Bow, E.J.2    Sepkowitz, K.A.3
  • 8
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera international trial (MInT) group
    • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7(5):379-391.
    • (2006) Lancet Oncol , vol.7 , Issue.5 , pp. 379-391
    • Pfreundschuh, M.1    Trumper, L.2    Osterborg, A.3
  • 9
    • 38549147027 scopus 로고    scopus 로고
    • Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
    • German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    • Pfreundschuh M, Schubert J, Ziepert M, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
    • (2008) Lancet Oncol , vol.9 , Issue.2 , pp. 105-116
    • Pfreundschuh, M.1    Schubert, J.2    Ziepert, M.3
  • 10
    • 34547670214 scopus 로고    scopus 로고
    • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
    • Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158-3167.
    • (2007) J Clin Oncol , vol.25 , Issue.21 , pp. 3158-3167
    • Kuderer, N.M.1    Dale, D.C.2    Crawford, J.3    Lyman, G.H.4
  • 11
    • 33745989223 scopus 로고    scopus 로고
    • 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
    • Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
    • (2006) J Clin Oncol , vol.24 , Issue.19 , pp. 3187-3205
    • Smith, T.J.1    Khatcheressian, J.2    Lyman, G.H.3
  • 12
    • 70450159652 scopus 로고    scopus 로고
    • Pegfilgrastim-a health economic model to assess overall cost-effectiveness
    • Borget I, Di Palma M, Leonard R. Pegfilgrastim-a health economic model to assess overall cost-effectiveness. Eur J Hospital Pharm Prac. 2009;15:58-61.
    • (2009) Eur J Hospital Pharm Prac , vol.15 , pp. 58-61
    • Borget, I.1    Di Palma, M.2    Leonard, R.3
  • 13
    • 41549115442 scopus 로고    scopus 로고
    • Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
    • Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008;11(2):172-179.
    • (2008) Value Health , vol.11 , Issue.2 , pp. 172-179
    • Eldar-Lissai, A.1    Cosler, L.E.2    Culakova, E.3    Lyman, G.H.4
  • 14
    • 64249170087 scopus 로고    scopus 로고
    • Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States
    • Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25(2):401-411.
    • (2009) Curr Med Res Opin , vol.25 , Issue.2 , pp. 401-411
    • Lyman, G.1    Lalla, A.2    Barron, R.3    Dubois, R.W.4
  • 15
    • 66949127931 scopus 로고    scopus 로고
    • Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States
    • Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther. 2009;31(5):1092-1104.
    • (2009) Clin Ther , vol.31 , Issue.5 , pp. 1092-1104
    • Lyman, G.H.1    Lalla, A.2    Barron, R.L.3    Dubois, R.W.4
  • 16
    • 70349897133 scopus 로고    scopus 로고
    • The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK
    • Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy. 2009;7(3):193-205.
    • (2009) Appl Health Econ Health Policy , vol.7 , Issue.3 , pp. 193-205
    • Liu, Z.1    Doan, Q.V.2    Malin, J.3    Leonard, R.4
  • 17
    • 60349114096 scopus 로고    scopus 로고
    • Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy
    • Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009;12(2):217-225.
    • (2009) Value Health , vol.12 , Issue.2 , pp. 217-225
    • Ramsey, S.D.1    Liu, Z.2    Boer, R.3
  • 18
    • 67649126886 scopus 로고    scopus 로고
    • Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients
    • Danova M, Chiroli S, Rosti G, Doan QV. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori. 2009;95(2):219-226.
    • (2009) Tumori , vol.95 , Issue.2 , pp. 219-226
    • Danova, M.1    Chiroli, S.2    Rosti, G.3    Doan, Q.V.4
  • 19
    • 0042914721 scopus 로고    scopus 로고
    • CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma
    • Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3041-3050.
    • (2003) J Clin Oncol , vol.21 , Issue.16 , pp. 3041-3050
    • Doorduijn, J.K.1    Van Der Holt, B.2    Van Imhoff, G.W.3
  • 20
    • 0030964191 scopus 로고    scopus 로고
    • Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
    • Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997;89(11):3974-3979.
    • (1997) Blood , vol.89 , Issue.11 , pp. 3974-3979
    • Zinzani, P.L.1    Pavone, E.2    Storti, S.3
  • 21
    • 0026667676 scopus 로고
    • Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial
    • Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992;80(6):1430-1436.
    • (1992) Blood , vol.80 , Issue.6 , pp. 1430-1436
    • Pettengell, R.1    Gurney, H.2    Radford, J.A.3
  • 22
    • 84863902271 scopus 로고    scopus 로고
    • Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy
    • Chan KKW, Siu E, Krahn MD, Imrie K, Alibhai SMH. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol. 2012;30(10):1064-1071.
    • (2012) J Clin Oncol , vol.30 , Issue.10 , pp. 1064-1071
    • Chan, K.K.W.1    Siu, E.2    Krahn, M.D.3    Imrie, K.4    Alibhai, S.M.H.5
  • 23
    • 33645810425 scopus 로고    scopus 로고
    • Good practice guidelines for decision-analytic modelling in health technology assessment: A review and consolidation of quality assessment
    • Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355-371.
    • (2006) Pharmacoeconomics , vol.24 , Issue.4 , pp. 355-371
    • Philips, Z.1    Bojke, L.2    Sculpher, M.3    Claxton, K.4    Golder, S.5
  • 25
    • 2942746370 scopus 로고    scopus 로고
    • Granulopoiesisstimulating factors to prevent adverse effects in the treatment of malignant lymphoma
    • Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesisstimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008;4:CD003189.
    • (2008) Cochrane Database Syst Rev , vol.4
    • Bohlius, J.1    Herbst, C.2    Reiser, M.3    Schwarzer, G.4    Engert, A.5
  • 26
    • 34548789514 scopus 로고    scopus 로고
    • Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection
    • Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400-411.
    • (2007) Ann Intern Med , vol.147 , Issue.6 , pp. 400-411
    • Sung, L.1    Nathan, P.C.2    Alibhai, S.M.3    Tomlinson, G.A.4    Beyene, J.5
  • 27
    • 77956400375 scopus 로고    scopus 로고
    • Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review
    • Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28(17):2914-2924.
    • (2010) J Clin Oncol , vol.28 , Issue.17 , pp. 2914-2924
    • Lyman, G.H.1    Dale, D.C.2    Wolff, D.A.3
  • 28
    • 85037866482 scopus 로고    scopus 로고
    • Ontario Ministry of Health and Long-Term Care Accessed March 2, 2013
    • Ontario Ministry of Health and Long-Term Care. Ontario Public Drug Programs Formulary. http://www.health.gov.on.ca/english/providers/program/drugs/ odbf-mn.html. Accessed March 2, 2013.
    • Ontario Public Drug Programs Formulary
  • 29
    • 76249099525 scopus 로고    scopus 로고
    • Evaluation of direct medical costs of hospitalization for febrile neutropenia
    • Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer. 2010;116(3):742-748.
    • (2010) Cancer , vol.116 , Issue.3 , pp. 742-748
    • Lathia, N.1    Mittmann, N.2    Deangelis, C.3
  • 30
    • 22444443711 scopus 로고    scopus 로고
    • Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy
    • Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol. 2005;75(2):116-123.
    • (2005) Eur J Haematol , vol.75 , Issue.2 , pp. 116-123
    • Doorduijn, J.1    Buijt, I.2    Holt, B.3    Steijaert, M.4    Uyl-De Groot, C.5    Sonneveld, P.6
  • 32
    • 0037313173 scopus 로고    scopus 로고
    • Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma
    • Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21(3):514-519.
    • (2003) J Clin Oncol , vol.21 , Issue.3 , pp. 514-519
    • Vose, J.M.1    Crump, M.2    Lazarus, H.3
  • 33
    • 17644379037 scopus 로고    scopus 로고
    • Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
    • Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916-1924.
    • (2005) Cancer , vol.103 , Issue.9 , pp. 1916-1924
    • Caggiano, V.1    Weiss, R.V.2    Rickert, T.S.3    Linde-Zwirble, W.T.4
  • 34
    • 24344445873 scopus 로고    scopus 로고
    • Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/-Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas
    • Cullen M. Steven N. Billingham L. et al. Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/-Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353(10):988-998.
    • (2005) N Engl J Med , vol.353 , Issue.10 , pp. 988-998
    • Cullen, M.1    Steven, N.2    Billingham, L.3
  • 35
    • 0036532256 scopus 로고    scopus 로고
    • Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis
    • Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406-411.
    • (2002) Am J Med , vol.112 , Issue.5 , pp. 406-411
    • Lyman, G.H.1    Kuderer, N.M.2    Djulbegovic, B.3
  • 36
    • 33746007143 scopus 로고    scopus 로고
    • Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer
    • Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19):2991-2997.
    • (2006) J Clin Oncol , vol.24 , Issue.19 , pp. 2991-2997
    • Timmer-Bonte, J.N.1    Adang, E.M.2    Smit, H.J.3
  • 37
    • 33745982067 scopus 로고    scopus 로고
    • Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    • Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127.
    • (2006) J Clin Oncol , vol.24 , Issue.19 , pp. 3121-3127
    • Habermann, T.M.1    Weller, E.A.2    Morrison, V.A.3
  • 38
    • 33644554514 scopus 로고    scopus 로고
    • The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies
    • Cherif H, Johansson E, Bjorkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica. 2006;91(2):215-222.
    • (2006) Haematologica , vol.91 , Issue.2 , pp. 215-222
    • Cherif, H.1    Johansson, E.2    Bjorkholm, M.3    Kalin, M.4
  • 39
    • 41849097436 scopus 로고    scopus 로고
    • Management of febrile neutropenia in solid tumours and lymphomas using the multinational association for supportive care in cancer (MASCC) risk index: Feasibility and safety in routine clinical practice
    • Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the multinational association for supportive care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2008;16(5):485-491.
    • (2008) Support Care Cancer , vol.16 , Issue.5 , pp. 485-491
    • Innes, H.1    Lim, S.L.2    Hall, A.3    Chan, S.Y.4    Bhalla, N.5    Marshall, E.6
  • 40
    • 33748661910 scopus 로고    scopus 로고
    • Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications
    • Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24(25):4129-4134.
    • (2006) J Clin Oncol , vol.24 , Issue.25 , pp. 4129-4134
    • Klastersky, J.1    Paesmans, M.2    Georgala, A.3
  • 41
    • 33846375918 scopus 로고    scopus 로고
    • Bank of Canada Accessed March 2, 2013
    • Bank of Canada. Inflation Calculator. http://www.bankofcanada.ca/rates/ related/inflation-calculator/. Accessed March 2, 2013.
    • Inflation Calculator
  • 42
    • 0035202991 scopus 로고    scopus 로고
    • Cost effectiveness of treatment options in advanced breast cancer in the UK
    • Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001;19(11):1091-1102.
    • (2001) Pharmacoeconomics , vol.19 , Issue.11 , pp. 1091-1102
    • Brown, R.E.1    Hutton, J.2    Burrell, A.3
  • 43
    • 79959926382 scopus 로고    scopus 로고
    • Costeffectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the united kingdom
    • Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R. Costeffectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the united kingdom. Value Health. 2011;14(4):465-474.
    • (2011) Value Health , vol.14 , Issue.4 , pp. 465-474
    • Whyte, S.1    Cooper, K.L.2    Stevenson, M.D.3    Madan, J.4    Akehurst, R.5
  • 44
    • 0347985317 scopus 로고    scopus 로고
    • Chemotherapy-induced neutropenia risks consequences and new directions for its management
    • Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia risks, consequences, and new directions for its management. Cancer. 2004;100(2):228-237.
    • (2004) Cancer , vol.100 , Issue.2 , pp. 228-237
    • Crawford, J.1    Dale, D.C.2    Lyman, G.H.3
  • 45
    • 0026575912 scopus 로고
    • How attractive does a new technology have to be to warrant adoption and utilization Tentative guidelines for using clinical and economic evaluations
    • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473-481.
    • (1992) CMAJ , vol.146 , Issue.4 , pp. 473-481
    • Laupacis, A.1    Feeny, D.2    Detsky, A.S.3    Tugwell, P.X.4
  • 46
    • 65549153613 scopus 로고    scopus 로고
    • Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing
    • Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol. 2009;27(13):2111-2113.
    • (2009) J Clin Oncol , vol.27 , Issue.13 , pp. 2111-2113
    • Hillner, B.E.1    Smith, T.J.2
  • 47
    • 41149171625 scopus 로고    scopus 로고
    • What does the value of modern medicine say about the $50,000 per qualityadjusted life-year decision rule
    • Braithwaite RS, Meltzer DO, King JT, Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per qualityadjusted life-year decision rule Med Care. 2008;46(4):349-356.
    • (2008) Med Care , vol.46 , Issue.4 , pp. 349-356
    • Braithwaite, R.S.1    Meltzer, D.O.2    King Jr., J.T.3    Leslie, D.4    Roberts, M.S.5
  • 48
    • 79959745514 scopus 로고    scopus 로고
    • Use of colony-stimulating factors with chemotherapy: Ppportunities for cost savings and improved outcomes
    • Potosky AL, Malin JL, Kim B, et al. Use of colony-stimulating factors with chemotherapy: ppportunities for cost savings and improved outcomes. J Natl Cancer Inst. 2011;103(12):979-982.
    • (2011) J Natl Cancer Inst , vol.103 , Issue.12 , pp. 979-982
    • Potosky, A.L.1    Malin, J.L.2    Kim, B.3
  • 49
    • 79957492218 scopus 로고    scopus 로고
    • Bending the cost curve in cancer care
    • Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060-2065.
    • (2011) N Engl J Med , vol.364 , Issue.21 , pp. 2060-2065
    • Smith, T.J.1    Hillner, B.E.2
  • 50
    • 85081799745 scopus 로고    scopus 로고
    • Amgen Inc Accessed July 23, 2012
    • Amgen Inc. Amgen media news release. http://www.amgen.com/media/media-pr- detail.jspyear=2012&releaseID=1653300. Accessed July 23, 2012.
    • Amgen Media News Release


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.